Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

7.7%

13 terminated/withdrawn out of 168 trials

Success Rate

71.7%

-14.8% vs industry average

Late-Stage Pipeline

15%

25 trials in Phase 3/4

Results Transparency

0%

0 of 33 completed trials have results

Key Signals

14 recruiting11 terminated

Enrollment Performance

Analytics

Phase 1
89(53.9%)
Phase 2
50(30.3%)
Phase 3
25(15.2%)
N/A
1(0.6%)
165Total
Phase 1(89)
Phase 2(50)
Phase 3(25)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (168)

Showing 20 of 168 trials
NCT07165886Phase 2Recruiting

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Role: lead

NCT07532655Phase 1Not Yet Recruiting

A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants

Role: lead

NCT07508462Phase 1Completed

A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

Role: lead

NCT07508501Phase 1Completed

Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets

Role: lead

NCT07418736Phase 2Recruiting

A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

Role: lead

NCT07412353Phase 1Recruiting

A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085

Role: lead

NCT07282509Phase 1Not Yet Recruiting

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

Role: lead

NCT07241936Phase 1Recruiting

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

Role: lead

NCT07163364Phase 3Not Yet Recruiting

A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)

Role: lead

NCT06947291Phase 2Recruiting

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Role: lead

NCT07117435Phase 1Recruiting

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Role: lead

NCT07116824Phase 2Not Yet Recruiting

HB1801 Combined Treatment of HER2-positive Breast Cancer

Role: lead

NCT06688435Phase 1Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

Role: lead

NCT07083505Phase 2Not Yet Recruiting

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

Role: lead

NCT06161844Phase 3Completed

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

Role: lead

NCT06562894Phase 2Not Yet Recruiting

Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

Role: collaborator

NCT04668690Phase 3Active Not Recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Role: lead

NCT06957379Phase 2Active Not Recruiting

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Role: lead

NCT06941142Phase 1Not Yet Recruiting

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Role: lead

NCT06929325Phase 3Not Yet Recruiting

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Role: lead